학술논문

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
Document Type
Article
Source
In: The Lancet. (The Lancet, 2023)
Subject
Language
English
ISSN
1474547X
01406736